Literature DB >> 14739094

Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis.

Jens H Henriksen1, Flemming Bendtsen, Erik Feldager Hansen, Søren Møller.   

Abstract

BACKGROUND/AIMS: Earlier studies have shown a prolonged frequency-adjusted Q-T interval (QTc>0.440 s(1/2)) in a substantial fraction of patients with cirrhosis. The effect of beta-blockade on QTc is unknown, and its determination was the aim of the study.
METHODS: Seventeen patients with cirrhosis received 80 mg propranolol orally during a haemodynamic investigation with measurements at baseline and 90 min after propranolol ingestion.
RESULTS: Beta-blockade reduced cardiac output (-21%, P<0.001), heart rate (-20%, P<0.001), and the hepatic venous pressure gradient (HVPG, -17%, P<0.02). The mean QTc=0.460 s(1/2) was prolonged compared to 0.410 s(1/2) in age-matched controls (P<0.01). Whereas QTc decreased during beta-blockade in the cirrhotic patients (from 0.460 to 0.440 s(1/2), P<0.01), no effect was found in the subgroup with normal QTc (0.429 vs. 0.422 s(1/2), ns), and a reduction was seen in the patients with prolonged QTc (from 0.488 to 0.456 s(1/2), P<0.01). The percentage decrease in QTc was related to the reduction in HVPG (r=0.48, P=0.03) and cardiac output (r=0.56, P=0.02).
CONCLUSIONS: Acute non-selective beta-blockade reduces prolonged QTc towards normal values in patients with cirrhosis. The clinical significance of QTc reduction in arrhythmia is a topic for future research.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14739094     DOI: 10.1016/j.jhep.2003.10.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  21 in total

1.  QT interval prolongation in end-stage liver disease cannot be explained by nonhepatic factors.

Authors:  Divyang Patel; Prabhpreet Singh; William Katz; Christopher Hughes; Kapil Chopra; Jan Němec
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-04-24       Impact factor: 1.468

Review 2.  Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients.

Authors:  Suehana Rahman; Susan V Mallett
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  [Hepatocardiac disorders : Interactions between two organ systems].

Authors:  T Horvatits; A Drolz; K Rutter; K Roedl; S Kluge; V Fuhrmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-06-13       Impact factor: 0.840

Review 4.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

5.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

Review 6.  Cirrhotic Multiorgan Syndrome.

Authors:  Søren Møller; Flemming Bendtsen
Journal:  Dig Dis Sci       Date:  2015-06-26       Impact factor: 3.199

7.  High Flow-Mediated Vasodilatation Predicts Pulmonary Edema in Liver Transplant Patients.

Authors:  Shyh-Ming Chen; Chao-Long Chen; Han-Tan Chai; Chee-Chien Yong; Hsien-Wen Hsu; Yu-Fan Cheng; Morgan Fu; Yu-Tung Anton Huang; Chi-Ling Hang
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

Review 8.  Cardiopulmonary complications in chronic liver disease.

Authors:  Soren Moller; Jens H Henriksen
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

9.  Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis?

Authors:  Mara Barbosa; Joana Guardado; Carla Marinho; Bruno Rosa; Isabel Quelhas; António Lourenço; José Cotter
Journal:  World J Hepatol       Date:  2016-01-28

10.  Cirrhotic cardiomyopathy: review of pathophysiology and treatment.

Authors:  Maneerat Chayanupatkul; Suthat Liangpunsakul
Journal:  Hepatol Int       Date:  2014-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.